Evidence map›Paper›PMID 32709406›Full record

ReviewTrends in pharmacological sciences2020

Mesenchymal Stem Cell Immunomodulation: Mechanisms and Therapeutic Potential.

Na Song, Martijn Scholtemeijer, Khalid Shah

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Trends in pharmacological sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06021067 (Dead Mesenchymal Stem Cells for the Treatment of Radiation Lung Injury), which is not on this map. Cited by 603 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
603citing papers in PubMed, 7 pooled it
55.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06021067 phase1 / phase2unknown statusnot on this mapstarted 2023, after this paper: background citation

Dead Mesenchymal Stem Cells for the Treatment of Radiation Lung Injury

TypeinterventionalSponsorSichuan UniversityRan2023 to 2024Enrolled15ConditionsRadiation Lung InjuryArmsDeath mesenchymal stem cell
3 · Its place in the literature

Who cites it

603 citing papers in PubMed, 7 syntheses or guidelines pooled it, 967 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

543 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Na SongCenter for Stem Cell Therapeutics and Imaging (CSTI), Harvard Medical School, Boston, MA 02115, USA; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China.
Martijn ScholtemeijerCenter for Stem Cell Therapeutics and Imaging (CSTI), Harvard Medical School, Boston, MA 02115, USA; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Khalid ShahCenter for Stem Cell Therapeutics and Imaging (CSTI), Harvard Medical School, Boston, MA 02115, USA; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA. Electronic address: kshah@bwh.harvard.edu.
Brigham and Women's Hospital · USHarvard Stem Cell Institute · US

Funding

In vivo imaging of the stem cell loaded oncolytic viruses for cancer therapyR01CA204720 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI SHAH, KHALID A · 2016 to 2020
$1.9M
Engineered and Encapsulated Stem Cells for Resected Brain TumorsR01NS107857 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI SHAH, KHALID A · 2019 to 2023
$1.9M
NCI NIH HHS R01 CA204720NINDS NIH HHS R01 NS107857
6 · The paper itself

Abstract

Mesenchymal stem/stromal cells (MSCs) are multipotent cells that are emerging as the most promising means of allogeneic cell therapy. MSCs have inherent immunomodulatory characteristics, trophic activity, high invitro self-renewal ability, and can be readily engineered to enhance their immunomodulatory functions. MSCs affect the functions of most immune effector cells via direct contact with immune cells and local microenvironmental factors. Previous studies have confirmed that the immunomodulatory effects of MSCs are mainly communicated via MSC-secreted cytokines; however, apoptotic and metabolically inactivated MSCs have more recently been shown to possess immunomodulatory potential, in which regulatory T cells and monocytes play a key role. We review the immunomodulatory aspects of naïve and engineered MSCs, and discuss strategies for increasing the potential of successfully using MSCs in clinical settings.

Indexed as

Mesenchymal Stem CellsCytokinesImmunomodulationT-Lymphocytes, RegulatoryCytokinesengineeringimmunomodulationmesenchymal stem cellstherapeutics

Identifiers

PMID32709406
PMCPMC7751844
OpenAlexW3043861550

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.